Oncimmune (LON:ONC)

Oncimmune (LON:ONC)

Share Price
100.00 p
0 (0.00 %)
Market Cap
£63.25 m
Proactive Investors - Run By Investors For Investors


Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and...

Market: AIM:ONC
52-week High/Low: 138.50p / 77.00p
Sector: Pharma & Biotech
Market Cap: £63.25 m
Website: oncimmune.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Oncimmune

Oncimmune Snapshot

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT® Lung and EarlyCDT® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. The study met its primary endpoint - showing that the use of EarlyCDT Lung with subsequent X-ray and computerised tomography (CT) scan reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Current Products & Services:

EarlyCDT® Lung - a blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

EarlyCDT® Liver - a blood test to aid in the detection and confirmation of hepatocellular carcinoma (HCC), in association with imaging, in high-risk patients with liver lesions of all sizes.

Serotag® Platform - Oncimmune’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

NavigAID for Autoimmune Disease - stratifies patients for improved therapeutic success based on the specific characteristics of their individual autoimmune disease, including the detection of biomarkers that are central to the disease’s pathology - autoantibodies.

NavigAID for Immuno-Oncology - able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy, helping pharmaceutical and biotech companies develop safer, more effective immunotherapies.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China.

Oncimmune has distribution in the folllowing countries:

Asia - China, Hong Kong, India, Korea, Singapore, Taiwan
EMEA - Denmark, France, Germany, Israel, Italy, Norway, Poland, Spain, Sweden, Turkey, UK


Meinhard Schmidt - Non-Executive Chairman

Mr. Schmidt is an executive and entrepreneur with more than 25 years of international experience in the healthcare, diagnostics and medical devices industries. Between 1998 and 2008 he was at Roche Diagnostics where he held various global senior leadership roles in Diabetes Care, Laboratory- and PoC-Diagnostics. From 2008 till 2011 he worked as an executive and CEO at Straumann Institute/Switzerland, responsible for the world-wide “Digitalization” of the Dental industry. He is currently active as an Independent Healthcare Professional providing active board engagement as Chairman a/o NED in public and private MedTech and LifeScience companies; consulting to top management teams to improve industrialization, commercialization and digitalisation processes; consulting investors (Private Equity/Venture Capital) on identification of new investment and acquisition targets in the global healthcare industries. He held positions in Germany, Netherlands, USA, Canada, UK, Sweden, Ireland and Switzerland and is currently active as Chairman, Board Director and Adviser at several companies in Europe, Asia and USA.


Dr. Adam Hill - Chief Executive Officer

Dr. Adam M Hill MB PhD is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam is a Visiting Professor in Global Health Innovation at Imperial College London, sits on the Value Creation Committee of Imperial College Health Partners and is Non Executive Director of Myrecovery.ai.

Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.


Tim Bunting - Non-Executive Director

Tim joined Balderton Capital (UK) LLP as a General Partner in 2007. He was previously a partner of Goldman Sachs where he spent 18 years. At Goldman Sachs, Tim held various roles including Global Head of Equity Capital Markets (2002 to 2005) and Vice-Chairman of Goldman Sachs International (2005 to 2006). Tim is also a Trustee of the Rainbow Trust Children’s Charity ; the Paul Hamlyn Foundation and the Royal Opera House. Tim is a graduate of the University of Cambridge.


Geoffrey Hamilton-Fairley - Non-Exective Vice Chairman

Mr. Hamilton-Fairley has an entrepreneurial career that started in 1982 when Geoffrey founded a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon). In 1988, he joined the board of Abingdon as CEO to manage the Company’s portfolio of media and technology investments, and subsequently became sole owner having acquired Abingdon from its institutional shareholders. Abingdon had a number of quoted and unquoted investments.

In 1998 he launched Premium TV (PTV) securing a contractual joint venture with Eurosport to create “British Eurosport”. Later that year PTV was acquired by NTL (now Virgin Media). As CEO of PTV Geoffrey developed the largest integrated broadband and internet sports broadcasting platform in the world at that time. Over the past ten years Geoffrey has developed Oncimmune Limited, serving as its Executive Chairman, CEO and now Vice Chairman. Geoffrey is also a senior research fellow at the International Prevention Research Institute. His personal commitment to cancer detection can be traced to his father, the first medical oncologist in the United Kingdom.

Julian Hirst - Independent Non-Executive Director

Julian is a seasoned finance executive with experience across a broad range of corporate finance transactions including equity private placements, initial public offerings, public debt and equity issues, mergers and acquisitions, trade sales, strategic partnerships and restructurings. Julian is currently the Corporate Finance Director of Immunocore Limited, a leading UK biotechnology company specialising in immuno-oncology. On a part-time basis, he is also the Joint Head of Technikos, a partnership which manages stakes in biomedical engineering spin-out companies from Oxford University. Prior to this, Julian held senior corporate finance positions, spanning a period of over 25 years, at several of the leading global investment banks including UBS Warburg, Morgan Stanley and Lehman Brothers.


Dr. Annalisa Jenkins - Senior Independent Non-Executive Director

Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, Cocoon Biotech Inc. (Non Executive Chair), Cellmedica (Non-Executive Chair), Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.


Dr. Carsten Schroeder - Independent Non-Executive Director

Dr. Schroeder has 25 years of senior leadership experience in the life sciences industry covering pharmaceuticals, medical device and in vitro diagnostic. Since 2014 he has been President of the Diagnostic Division at Grifols, S.A. where he is responsible for global commercial operations and overall strategy, including leading its growth and innovation in Transfusion Medicine and Clincial Diagnostic. Prior to that, and before its acquisition by Grifols, Carsten was President of Novartis Diagnostics. Carsten joined Novartis Diagnostics in 2010 as Vice President of Commercial Operations for the EMEA region where he oversaw expansion into new markets. During his time at Novartis he was a member of the Vaccines & Diagnostic Division Executive Committee and served as Site Head for its Emeryville campus in California. Carsten has also held executive positions with Boston Scientific, Mallinckrodt (now Covidien) and Boehringer Ingelheim. Mr. Schroeder holds an MBA from the European School of Management in Paris (ESCP) and a Bachelor of Arts in Economics from the University of Cologne in Germany.


Richard Sharp - Non-Executive Director

Richard graduated from Oxford University and began his professional career in 1978 working for JPMorgan in UK Banking, then in Investment Banking and Derivatives. In 1985, Richard joined Goldman Sachs in London and variously served as Head of Capital Markets, Head of UK investment Banking and Head of European Private Equity and Mezzanine Investing. Richard left Goldman in 2007 to found and run DII Capital LLP. Richard has been separately a trustee of the Royal Marsden Capital Fund and a trustee of the Institute of Cancer Research. In the summer of 2013, Richard became an External Appointee of HM Treasury on the Financial Policy Committee of the Bank of England which is responsible for Macro-Prudential Supervision in the UK.


Dr. Cheung To - Non-Executive Director

Dr. Cheung To is an entrepreneur with over 25 years’ of extensive experience in biotechnology research and instinctive knowledge of the development of the world’s, and China’s, biotechnology markets. He co-founded and is Chairman of Gene Group Co. Ltd., a group that now includes several major companies including: Gene Co. Ltd., one of the largest professional service and distribution provider for the medical, life science, pharmaceutical and biotech research sectors in China; Ecotek Co. Ltd., a professional services company to the agricultural and environmental research sectors in China; Genetech (Shanghai) Co. Ltd., a business focused on R&D, manufacturing, marketing & distribution of molecular and cellular diagnostic products in the fields of pathology, oncology, heamatology and molecular genetics; Ebiotrade.com, a Biotech portal and e-commerce provider; and Baygene Co. Ltd., a company focused on R&D, manufacturing and distribution of life-science research products.

Dr. Cheung To obtained his Ph.D from the University of Hong Kong, Medical Faculty, Dept. of Biochemistry in 1996, and he was awarded one of the experts in the prestige China’s National “Recruitment Program of Global Experts” (known as “the Thousand Talents Program”) in 2010, in recognition of his contribution towards the industries and society.


Andrew Unitt - Independent Non-Executive Director

Andrew was Chief Financial Officer at the University of Nottingham, a major shareholder in Oncimmune, until July 2016. Prior to working in higher education at the university, Andrew was a finance director for 20 years in a wide range of industries. His more recent background includes 11 years at Boots plc, where he was Finance Director for 4 years of Boots Healthcare International, its over the counter medicines business. He has also held a number of non executive directorships in the NHS and private sector.


Shares Issued

As at 30th April 2019, the number of ordinary shares in issue was 63,250,217.

Major Shareholders

As at 30th April 2019, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:


No of Ordinary Shares


Balderton Capital III, LP1



Genostics Company Ltd2



Richard Sharp



Ruffer LLP



Geoffrey Hamilton-Fairley



FIL Investment International



Timothy Bunting



Milton Asset Management



University of Nottingham



1 Mr Bunting is a partner of Balderton Capital (UK) LLP the investment adviser to Balderton Capital Partners III, LP.
2 Cheung To is a shareholder and director of Genostics Company Ltd.


Director Shareholdings


No of Shares

No of Share Options

No of Warrants

Tim Bunting


Geoffrey Hamilton-Fairley




Adam Hill


Richard Sharp


Meinhard Schmidt




Shares not in Public Hands

In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 30th April 2019, 39.47% of the Company’s AIM securities was not in public hands.

Restrictions on Transfer of Aim Securities

There are no restrictions on the transfer of securities.

UK City Code on Takeovers and Mergers

Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.

Details of Other Exchanges or Trading Platforms

Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.

Page last updated: 9th May 2019

Oncimmune Limited

Email: [email protected]

Phone: +44 (0)115 8231869

Clinical Sciences Building
Nottingham City Hospital
Hucknall Road
United Kingdom


Zeus Capital Limited
10 Old Burlington Street
London W1S 3AG

82 King Street
Manchester M2 4WQ

Joint Brokers

Bryan Garnier & Co
Beaufort House, 15 St Botolph Street
London EC3A 7BB

Zeus Capital Limited
10 Old Burlington Street
London W1S 3AG


Grant Thornton UK LLP
Chartered Accountants, Statutory Auditor
Victoria House, 4th Floor
199 Avebury Boulevard
Milton Keynes

Solicitors to the Company

Peachey & Co LLP
95 Aldwych
London WC2B 4JF

Patent Attorneys to the Company

Boult Wade Tennant
Verulam Gardens
70 Gray’s Inn Road
London WC1X 8BT

Financial PR

Consilium Strategic Communications Limited
41 Lothbury
London EC2R 7HG

Company Registrars

Link Asset Services
34 Beckenham Road
Kent BR3 4TU

Columns Including ONC


Market Reports Including ONC

Video RSS



© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use